Marco Calvigioni, Edoardo Biancalana, C. Rossi, Diletta Mazzantini, F. Celandroni, Emilia Ghelardi, Anna Solini
tlooto Summary
The combined use of SGLT2 inhibitors and dipeptidyl‐peptidase four inhibitors seems to reduce the incidence of side effects of SGLT2 inhibitors in subjects with type 2 diabetes.
Abstract
A reduced compliance, due to urogenital minor infections, frequently compromises the clinical efficacy of SGLT2 inhibitors in subjects with type 2 diabetes (T2D). The combined use of SGLT2 inhibitors and dipeptidyl‐peptidase four inhibitors seems to reduce the incidence of such side effects. We evaluated how these drugs, alone or in combination, might influence resident urinary microbiota.
Citation format
CALVIGIONI, Marco, et al. Effect of SGLT2 inhibitors + DPP‐4 inhibitors on urine microbiota in type 2 diabetes. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2026, 42(1): e70127.